---
title: "TIANXIN PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 219 million yuan, a year-on-year increase of 48.13%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/238109064.md"
description: "According to the Zhitong Finance APP, TIANXIN PHARMA disclosed its first-quarter report for 2025, showing that the company achieved revenue of 619 million yuan, a year-on-year increase of 25.16%; net profit attributable to the parent company was 219 million yuan, a year-on-year increase of 48.13%; and net profit excluding non-recurring gains and losses was 209 million yuan, a year-on-year increase of 53.30%. The basic earnings per share were 0.50 yuan"
datetime: "2025-04-29T15:32:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238109064.md)
  - [en](https://longbridge.com/en/news/238109064.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238109064.md)
generator: "portal-rs"
---

# TIANXIN PHARMA released its first-quarter performance, with a net profit attributable to the parent company of 219 million yuan, a year-on-year increase of 48.13%

According to the Zhitong Finance APP, TIANXIN PHARMA (603235.SH) disclosed its first-quarter report for 2025, reporting revenue of 619 million yuan, a year-on-year increase of 25.16%; net profit attributable to shareholders of 219 million yuan, a year-on-year increase of 48.13%; and net profit excluding non-recurring items of 209 million yuan, a year-on-year increase of 53.30%. Basic earnings per share are 0.50 yuan

### Related Stocks

- [603235.CN](https://longbridge.com/en/quote/603235.CN.md)

## Related News & Research

- [APTN Shareholders Approve Shift Toward Pharma and Biotech Trading](https://longbridge.com/en/news/298871061.md)
- [Zcash: THORChain adds native ZEC and XMR chains with vaults and pools - By 04 Oct 2026](https://longbridge.com/en/news/298885237.md)
- [Whitehawk says PTK7 expression stays stable after standard care in EGFR wild-type NSCLC, supporting HWK-007 ADC targetability](https://longbridge.com/en/news/298851061.md)
- [Senegal eyes homemade satellites amid African space race](https://longbridge.com/en/news/298811883.md)
- [FDA Approves Tablet Form of Zanubrutinib for All Approved Indications](https://longbridge.com/en/news/298434766.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**